Skip to content

FDA Category 2 · restricted from compounding

This compound is on the FDA’s interim Section 503A Category 2 bulks list and cannot be legally compounded by US pharmacies. An HHS announcement in February 2026 signaled intent to restore several peptides to Category 1, but no Federal Register action has been published. Check the FDA PCAC schedule for updates.

Read the full regulatory context
PreclinicalGrowth HormoneSubQDaily during cyclePartial data

IGF-1 LR3

Long R3 IGF-1

Long-acting analog of IGF-1 with reduced IGFBP binding, producing sustained anabolic signaling.

§ 01   Overview

Overview

Long-acting analog of IGF-1 with reduced IGFBP binding, producing sustained anabolic signaling.

Research reagent status; no FDA trials. Used in bodybuilding communities.

§ 02   Mechanism

Mechanism of action

IGF-1 LR3 has an Arg3 substitution and an N-terminal Long peptide extension that reduces binding to IGF-binding proteins. This extends its half-life and free-fraction activity vs. native IGF-1.

  • 01Anabolic / hypertrophy signaling
  • 02Some reports of tissue repair support
  • 03Potent compared to native IGF-1

§ 03   Dosing

Dosing protocol

Standard Protocol

Vial
1 mg
BAC Water
1 ml BAC water
Dose Range
20 – 100 mcg per dose
Starting Dose
20 mcg
Route
SubQ
Timing
Post-workout
Frequency
Daily during cycle
Cycle
Short cycles (2–4 weeks) due to desensitization and hypoglycemia risk

§ 04   Evidence

Evidence & research

Preclinical

Research reagent status; no FDA trials. Used in bodybuilding communities.

FDA Status

Not FDA-approved. WADA prohibited.

§ 06   News

In the news

4 articles from the last 12 months · updates hourly

§ 07   Sourcing

Sourcing & supply

Regulatory status

Restricted from compounding

Placed on the FDA's 503A Category 2 list and cannot be lawfully compounded in the US. No brand pharmacy alternative exists. US buyers encounter only research-use-only (RUO) channels, which the FDA's Intended Use Doctrine treats as unapproved drug sales.

Research-use-only · 3

Research-use-only

Limitless Life Nootropics

'Only BBB-accredited peptide company' (since 2020). Claims three-lab third-party testing. Broad catalog.

BBB Accredited +1
Visit
Research-use-only

Core Peptides

Broad catalog, widest payment range. Mid-credibility: Knoji 2.5/5 and one scam-impersonation report.

Third-Party Testing1 flag on record
Visit
Research-use-only

Ascension Peptides

Among newer RUO vendors with cleaner credibility signals. SafeCert Labs (CLIA-certified) testing, 4.8 Trustpilot. US-only.

Third-Party Testing
Visit

Listings are informational, not endorsement. Verify credentials and flags against FDA and PCAB databases before purchasing. Full directory & how to verify →

§ 09   Safety

Safety & side effects

Side effects

  • 01Hypoglycemia
  • 02Injection site lump
  • 03Potential tumor-promoting signaling

Contraindications

  • 01Active or prior malignancy (IGF-1 signaling can be tumor-promoting)
  • 02Retinopathy

§ 10   Questions

IGF-1 LR3 FAQ

What is IGF-1 LR3?
Long-acting analog of IGF-1 with reduced IGFBP binding, producing sustained anabolic signaling. IGF-1 LR3 has an Arg3 substitution and an N-terminal Long peptide extension that reduces binding to IGF-binding proteins. This extends its half-life and free-fraction activity vs. native IGF-1.
What is IGF-1 LR3 used for?
Reported uses include anabolic / hypertrophy signaling, some reports of tissue repair support, and potent compared to native igf-1. Evidence strength is rated Preclinical — see the evidence section for detail.
How is IGF-1 LR3 dosed?
Commonly referenced dosing is 20 – 100 mcg per dose, typically daily during cycle, administered SubQ. This is educational reference only; consult a licensed clinician before use.
How do you reconstitute IGF-1 LR3?
For IGF-1 LR3, vials commonly come in 1 mg and a common reconstitution is 1 ml BAC water. Use the reconstitution calculator to convert any vial size and water volume into exact insulin-syringe units.
What are the side effects of IGF-1 LR3?
Commonly reported side effects include hypoglycemia, injection site lump, and potential tumor-promoting signaling. This list is not exhaustive.
Is IGF-1 LR3 legal?
Placed on the FDA's 503A Category 2 list and cannot be lawfully compounded in the US. No brand pharmacy alternative exists. US buyers encounter only research-use-only (RUO) channels, which the FDA's Intended Use Doctrine treats as unapproved drug sales. FDA status: Not FDA-approved. WADA prohibited..

This site is for educational and research purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide or supplement.